Sri Krishna Pharma received USFDA warning for cGMP norm violations
Posted on22 Apr 2016
Tags483 OBSERVATION, 483 observations, Cipla gets 483 observation for Indore unit, fda 483 observation, FORM 483, usfda 483 form
Comments0
The Hyderabad-based Sri Krishna Pharmaceuticals has been warned by US health regulator for violations of good manufacturing practices at its facility, including... Read More
Cipla gets 483 observation for Indore unit
Indian drug maker Cipla Ltd. has been served 483 observations by the US FDA for its Indore-based manufacturing unit as part of an... Read More